Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial.
- DOI
- 10.1016/j.esmogo.2026.100352
- Published
- 2026 Sep
- Container
- ESMO gastrointestinal oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmogo.2026.100352,
title = {Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial.},
author = {Shitara K and Enzinger P and Lordick F and Smyth E and Rha SY and Van Cutsem E and Xu RH and Strickler JH and Lee P and Klempner SJ},
year = {2026},
journal = {ESMO gastrointestinal oncology},
doi = {10.1016/j.esmogo.2026.100352},
url = {https://doi.org/10.1016/j.esmogo.2026.100352}
}RIS
TY - JOUR TI - Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial. AU - Shitara K AU - Enzinger P AU - Lordick F AU - Smyth E AU - Rha SY AU - Van Cutsem E AU - Xu RH AU - Strickler JH AU - Lee P AU - Klempner SJ PY - 2026 JO - ESMO gastrointestinal oncology DO - 10.1016/j.esmogo.2026.100352 UR - https://doi.org/10.1016/j.esmogo.2026.100352 ER -
APA
K, S., P, E., F, L., E, S., SY, R., E, V. C., RH, X., JH, S., P, L., & SJ, K. (2026). Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial.. ESMO gastrointestinal oncology. https://doi.org/10.1016/j.esmogo.2026.100352
Source records
- pubmed · retrieved 2026-09-26T18:02:12.075Z